Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bissonnette

Showing results (51-60 of 222) with videos related to

Pageof 23
Sort By:
Journal of Cutaneous Medicine and Surgery|January 8, 2010
Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE studyGordon Searles, Robert Bissonnette, Ian Landells, et al.
The Journal of Rheumatology. Supplement|November 3, 2011
Validity of quality of life measurement tools--from generic to disease-specificGeorge A Wells, Anthony S Russell, Boulos Haraoui, et al.
Journal of the American Academy of Dermatology|November 6, 2020
Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agentRobert Bissonnette, Linda Stein Gold, David S Rubenstein, et al.
Journal of the American Academy of Dermatology|November 26, 2003
Restoration of hair growth with topical diphencyprone in mouse and rat models of alopecia areataLiren Tang, Harvey Lui, John P Sundberg, et al.
The Journal of Dermatological Treatment|July 30, 2011
A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanerceptCharles W Lynde, Aditya K Gupta, Lyn Guenther, et al.
The Journal of Rheumatology. Supplement|November 3, 2011
Fatigue and quality of sleep in patients with immune-mediated inflammatory diseaseLesley A Graff, John R Walker, Anthony S Russell, et al.
Journal of the American Academy of Dermatology|March 7, 2021
Tapinarof-associated folliculitis is generally mild, self-limiting, and rarely interferes with therapyRobert Bissonnette, Linda Stein Gold, David S Rubenstein, et al.
Journal of the American Academy of Dermatology|March 7, 2021
The preponderance of evidence supports an aryl hydrocarbon receptor-dependent mechanism of action of tapinarofRobert Bissonnette, Linda Stein Gold, David S Rubenstein, et al.
Circulation. Cardiovascular Imaging|December 4, 2012
Effects of the tumor necrosis factor-α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trialRobert Bissonnette, Jean-Claude Tardif, François Harel, et al.
Journal of Cosmetic Dermatology|April 7, 2010
A double-blind study of tolerance and efficacy of a new urea-containing moisturizer in patients with atopic dermatitisRobert Bissonnette, Catherine Maari, Nathalie Provost, et al.
Pageof 23

Showing results (51-60 of 222) with videos related to

Sort By:
Pageof 23
Journal of Cutaneous Medicine and Surgery|January 8, 2010
Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE studyGordon Searles, Robert Bissonnette, Ian Landells, et al.
The Journal of Rheumatology. Supplement|November 3, 2011
Validity of quality of life measurement tools--from generic to disease-specificGeorge A Wells, Anthony S Russell, Boulos Haraoui, et al.
Journal of the American Academy of Dermatology|November 6, 2020
Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agentRobert Bissonnette, Linda Stein Gold, David S Rubenstein, et al.
Journal of the American Academy of Dermatology|November 26, 2003
Restoration of hair growth with topical diphencyprone in mouse and rat models of alopecia areataLiren Tang, Harvey Lui, John P Sundberg, et al.
The Journal of Dermatological Treatment|July 30, 2011
A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanerceptCharles W Lynde, Aditya K Gupta, Lyn Guenther, et al.
The Journal of Rheumatology. Supplement|November 3, 2011
Fatigue and quality of sleep in patients with immune-mediated inflammatory diseaseLesley A Graff, John R Walker, Anthony S Russell, et al.
Journal of the American Academy of Dermatology|March 7, 2021
Tapinarof-associated folliculitis is generally mild, self-limiting, and rarely interferes with therapyRobert Bissonnette, Linda Stein Gold, David S Rubenstein, et al.
Journal of the American Academy of Dermatology|March 7, 2021
The preponderance of evidence supports an aryl hydrocarbon receptor-dependent mechanism of action of tapinarofRobert Bissonnette, Linda Stein Gold, David S Rubenstein, et al.
Circulation. Cardiovascular Imaging|December 4, 2012
Effects of the tumor necrosis factor-α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trialRobert Bissonnette, Jean-Claude Tardif, François Harel, et al.
Journal of Cosmetic Dermatology|April 7, 2010
A double-blind study of tolerance and efficacy of a new urea-containing moisturizer in patients with atopic dermatitisRobert Bissonnette, Catherine Maari, Nathalie Provost, et al.
Pageof 23